Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 309-316

  Hauk, V ^a   Calafat, M ^a   Larocca, L ^a   Fraccaroli, L ^a   Grasso, E ^a   Ramhorst, R ^a   Leirós, C Pérez ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acinar cell apoptosis and clearance; Sj gren's syndrome; VIP

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ACINAR CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND;

ACINAR CELLS; ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; NF-KAPPA B; PHAGOCYTOSIS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SJOGREN'S SYNDROME; SUBMANDIBULAR GLAND; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 80855151626     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04478.x     Document Type: Article

References (41)

1. Ng WF, Bowman SJ, Griffiths B, on behalf of the UKPSSR study group. United Kingdom Primary Sjögren's Syndrome Registry - a united effort to tackle an orphan rheumatic disease. Rheumatology 2011; 50:32-9.
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11:229. doi:10.1186/ ar2669. Available at:
3. Fox RI. Sjögren's syndrome. Lancet 2005; 366:321-31.
4. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006; 2:252-2261.
5. Manoussakis MN, Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Ballière's Clin Rheumatol 2000; 14:73-95.
6. Konttinen Y, Porola P, Konttinen L, Laine M, Poduval P. Immunohistopathology of Sjögren's syndrome. Autoimmun Rev 2006; 6:16-20.
7. Törnwall J, Konttinen YT, Tuominen RK, Törnwall M. Protein kinase C expression in salivary gland acinar epithelial cells in Sjögren's syndrome. Lancet 1997; 349:1814-51.
8. Steinfeld SD, Appelboom T, Delporte C. Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002; 46:2249-51.
9. van Blokland SC, Versnel MA. Pathogenesis of Sögren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol 2002; 103:111-24.
10. Lee BH, Tudares MA, Nguyen CQ. Sjögren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp (Warsz) 2009; 57:57-66.
11. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 2008; 10:R22.
12. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Pérez Leirós C. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol 2005; 142:411-18.
13. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum 2006; 54:2300-5.
14. Berggreen E, Nylokken K, Delaleu N, Hajdaragic-Ibricevic H, Jonsson MV. Impaired vascular responses to parasympathetic nerve stimulation and muscarinic receptor activation in the submandibular gland in non-obese diabetic mice. Arthritis Res Ther 2009; 11:R18.
15. Rosignoli F, Roca V, Meiss R, Pregi N, Pérez Leirós C. Inhibition of calcium-calmodulin kinase restores nitric oxide production and signaling in submandibular glands of a mouse model of salivary dysfunction. Br J Pharmacol 2004; 143:1058-65.
16. Calafat M, Larocca L, Roca V etal. Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 2009; 11:R53. doi:10.1186/ar2671. Available at:
17. Ekström J. Autonomic control of salivary secretion. Proc Finn Dent Soc 1989; 85:323-31.
18. Månsson B, Nilsson BO, Ekström J. Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 1990; 101:853-8.
19. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann NY Acad Sci 2006; 1070:51-74.
20. Gonzalez-Rey E, Ganea D, Delgado M. Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Curr Opin Pharmacol 2010; 10:473-81.
21. Gomariz RP, Gutiérrez-Cañas I, Arranz A etal. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Des 2010; 16:1063-80.
22. Rosignoli F, Torroba M, Juarranz Y etal. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci 2006; 1070:525-30.
23. Lodde BM, Mineshiba F, Wang J etal. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren's syndrome. Ann Rheum Dis 2006; 65:195-200.
24. Larocca L, Hauk V, Calafat M etal. Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol Cell Endocrinol 2011; 333:112-18.
25. Larocca L, Calafat M, Roca V, Franchi AM, Pérez Leirós C. VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages. Int Immunopharmacol 2007; 7:1343-9.
26. Roca V, Larocca L, Calafat M etal. Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of NOD mice. Reproduction 2006; 132:931-8.
27. Jimeno R, Gomariz RP, Gutierrez-Cañas I, Martínez C, Juarranz Y, Leceta J. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88:734-45.
28. Dale E, Davis M, Faustman DL. A role for transcription factor NF-kB in autoimmunity: possible interactions of genes, sex and the immune response. Adv Physiol Educ 2006; 30:152-8.
29. Kim MJ, Joo KM, Chung YH etal. Vasoactive intestinal peptide (VIP) and VIP mRNA decrease in the cerebral cortex of nNOS knock-out(-/-) mice. Brain Res 2003; 978:233-40.
30. Strietzel FP, Lafaurie GI, Mendoza GR etal. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum 2011; 63:180-90.
31. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87:619-28.
32. Kong L, Ogawa N, McGuff HS etal. Bcl-2 family expression in salivary glands from patients with primary Sjögren's syndrome: involvement of Bax in salivary gland destruction. Clin Immunol Immunopathol 1998; 88:133-41.
33. Kong L, Ogawa N, Nakabayashi T etal. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997; 40:87-97.
34. Kong L, Robinson CP, Peck AB etal. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-SCID mice. Clin Exp Rheumatol 1998; 16:675-81.
35. Nguyen CQ, Cornelius JG, Cooper L etal. Identification of possible candidate genes regulating Sjögren's syndrome-associated autoimmunity: a potential role for TNFSF4 in autoimmune exocrinopathy. Arthritis Res Ther 2008; 10:R137. doi:10.1186/ar2560. Available at:
36. Vosters JL, Yin H, Roescher N, Kok MR, Tak PP, Chiorini JA. Local expression of tumor necrosis factor-receptor 1: immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome. Arthritis Res Ther 2009; 11:R189.
37. Krause S, Kuckelkorn U, Dörner T, Burmester GR, Feist E, Kloetzel PM. Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis 2006; 65:1021-7.
38. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-69.
39. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 2002; 51:2481-8.
40. Stoffels K, Overbergh L, Giulietti A etal. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J Autoimmun 2004; 23:9-15.
41. Marée AF, Komba M, Finegood DT, Edelstein-Keshet L. A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. J Appl Physiol 2008; 104:157-69.